IRWD - Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A
IEX Last Trade
5.05
-0.060 -1.188%
Share volume: 1,325,722
Last Updated: Fri 30 Aug 2024 09:59:57 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$5.11
-0.06
-1.17%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-04 | 2022-11-03 | 2023-02-16 | 2023-05-04 | 2023-08-09 | 2023-11-09 | 2024-02-16 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 975.690 M | 1.040 B | 1.101 B | 1.155 B | 603.220 M | 524.063 M | 471.073 M | 438.819 M | |
| Current Assets | 617.826 M | 698.994 M | 780.626 M | 866.374 M | 317.599 M | 253.610 M | 233.288 M | 208.174 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 9.854 M | 7.011 M | 7.715 M | 9.033 M | 22.500 M | 18.112 M | 12.012 M | 14.619 M | |
| Short Term Investments | 9.854 M | 7.011 M | 7.715 M | 9.033 M | 22.500 M | 18.112 M | 12.012 M | 14.619 M | |
| Total Receivables | 102.357 M | 116.545 M | 115.458 M | 115.749 M | 118.990 M | 124.546 M | 129.122 M | 72.015 M | |
| Current Cash | 504.365 M | 574.188 M | 656.203 M | 740.342 M | 175.321 M | 110.164 M | 92.154 M | 121.540 M | |
| Total Non-current Assets | 357.864 M | 341.350 M | 319.893 M | 288.903 M | 285.621 M | 270.453 M | 237.785 M | 230.645 M | |
| Property Plant Equipment | 6.964 M | 6.660 M | 6.288 M | 6.015 M | 5.876 M | 5.630 M | 5.585 M | 5.288 M | |
| Other Assets | 15.161 M | 15.302 M | 15.436 M | 820.000 K | 3.920 M | 3.823 M | 3.608 M | 3.398 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 4.096 M | 3.889 M | 3.682 M | 3.478 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 975.690 M | 1.040 B | 1.101 B | 1.155 B | 603.220 M | 524.063 M | 471.073 M | 438.819 M | |
| Total liabilities | 442.807 M | 449.281 M | 448.141 M | 448.425 M | 948.924 M | 847.279 M | 817.368 M | 769.337 M | |
| Total current liabilities | 23.298 M | 27.117 M | 25.525 M | 23.843 M | 305.390 M | 280.579 M | 276.101 M | 252.442 M | |
| Accounts Payable | 317.000 K | 795.000 K | 483.000 K | 118.000 K | 3.505 M | 4.698 M | 7.830 M | 6.222 M | |
| Other liabilities | 6.491 M | 9.227 M | 9.766 M | 11.824 M | 31.035 M | 30.948 M | 28.415 M | 29.414 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 199.083 M | 199.321 M | 199.560 M | 199.800 M | |
| Long term debt | 395.451 M | 395.850 M | 396.251 M | 396.653 M | 597.974 M | 523.141 M | 498.309 M | 473.477 M | |
| Other liabilities | 6.491 M | 9.227 M | 9.766 M | 11.824 M | 31.035 M | 30.948 M | 28.415 M | 29.414 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | -1.073 M | -2.463 M | 0.000 | 0.000 | |
| Total Shareholder equity | 532.883 M | 591.063 M | 652.378 M | 706.852 M | -345.704 M | -323.216 M | -346.295 M | -330.518 M | |
| Common stock | 153.304 M | 153.066 M | 153.273 M | 154.452 M | 155.367 M | 155.886 M | 156.035 M | 157.700 M | |
| Retained earnings | -795.560 M | -745.243 M | -696.376 M | -650.662 M | -1.713 B | -1.698 B | -1.699 B | -1.703 B |